Catalyst Calendar

Wed, Jun 10, 2026

1 updates

4:01 PM

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched

Enrollment • Phase 2Enrollment milestone Wed, Jun 10, 2026tectonictx.com

Thu, May 7, 2026

1 updates

TECX

4:01 PM

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”), and as

Enrollment • Phase 2tectonictx.com

Thu, Apr 23, 2026

1 updates

TECX

4:01 PM

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs),

tectonictx.com